A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients with Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures NCT02544763

A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of Cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with Tuberous Sclerosis Complex who experience inadequately-controlled seizures NCT02544763 How long is the study? Study length: 5 weeks of baseline and 16 weeks of treatment

Landmark decision as everolimus for refractory epilepsy in people with Tuberous Sclerosis Complex is accepted for use by NHS Scotland

  MEDIA RELEASE The Scottish Medicines Consortium (SMC) has announced today [Monday, 11 June] that everolimus will be available on prescription to treat refractory epilepsy in people aged two years and older with Tuberous Sclerosis Complex (TSC) in Scotland.   Maxine Smeaton, Chief Executive of

NHS England ignores evidence on everolimus for TSC-related epilepsy and says it will not fund treatment that changes lives

  NHS England has announced today [Saturday 7 July 2018] that it will not fund everolimus for the treatment of refractory epilepsy for people with Tuberous Sclerosis Complex (TSC) in England. The announcement comes less than a month after the Scottish Medicines Consortium (SMC) recommended

A response to the UK Government announcement today that medicinal cannabis products are to be legalised within the UK

  Today (Friday July 27) specialist doctors in the UK will be able to legally prescribe cannabis-derived medicinal products by the autumn, Home Secretary Sajid Javid has announced. According to media reports, those that meet safety and quality standards are to be made legal for